Highlights Oncternal Therapeutics, Inc.

Equities

ONCT

US68236P2065

Delayed Nasdaq Other stock markets 11:46:58 2024-05-14 EDT			5-day change	1st Jan Change
8.881 ^USD	+3.26%		+4.23%	-17.19%

05-09	Transcript : Oncternal Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024
05-09	Oncternal Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oncternal Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	05-09	CI
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer	04-18	CI
Oncternal Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-07	CI
Oncternal Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-07	CI
Oncternal Therapeutics, Inc. Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer	01-08	CI
Reverse Split: 1 of 20	01-07	FA
Oncternal Therapeutics, Inc. Updates the Status of its Phase 1/2 Study of ONCT-808, a ROR1-Targeting Autologous CAR T, in Patients with Relapsed or Refractory Aggressive B-Cell Lymphoma	12-26	CI
Oncternal Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Oncternal Therapeutics Announces FDA Granted Fast Track Designation for ONCT-534 for the Treatment of Metastatic Castration-Resistant Prostate Cancer	23-10-26	CI
Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of Dual-Action AR Inhibitor, ONCT-534, in Patients with Metastatic Castration-Resistant Prostate Cancer	23-10-05	CI
Oncternal Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Oncternal Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2 Study of ROR1 Targeting Autologous CAR T, ONCT-808, in Patients with Relapsed or Refractory Aggressive B-Cell Lymphoma	23-06-06	CI
Oncternal Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
Oncternal Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-09	CI
Oncternal Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-09	CI
Oncternal Therapeutics, Inc. Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib	22-12-10	CI
Oncternal Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-03	CI
Oncternal Therapeutics to Present Updated Interim Phase 1/2 Data for Zilovertamab in Combination with Ibrutinib in an Oral Session at ASH 2022	22-11-03	CI
Oncternal Therapeutics Says US FDA Clears Study of New Drug for Treatment of Aggressive B Cell Lymphoma; Shares Rise	22-10-03	MT
Oncternal Therapeutics Receives IND Clearance for ONCT-808, Its Autologous Car T Product Candidate Targeting Ror1 for the Treatment of Aggressive B Cell Lymphoma	22-10-03	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Oncternal Therapeutics, Inc.

Equities

ONCT

US68236P2065

Highlights

Filters